Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q3 2024 Earnings Call Transcript
Megan LeDuc: Good evening. I'm Megan LeDuc, Manager of Investor Relations at Ginkgo Bioworks. I'm joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO.
Ginkgo Bioworks Holdings Inc. (DNA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Anson Investments Amin Nathoo And Moez Kassam | 0 | $0 | -100% | 0% |
| 2. | 0 | $0 | -100% | 0% | |
| 3. | Anson Investments Amin Nathoo And Moez Kassam | 0 | $0 | -100% | 0% |
| 4. | Ghisallo Capital Management Michael Germino | 0 | $0 | -100% | 0% |
| 5. | Davidson Kempner Thomas Lenox Kempner | 0 | $0 | -100% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.82 | 625,000 | Director | 2,356,874 | 2024-05-15 | Filing | |
| $0.91 | 297,619 | Director | 718,540 | 2024-05-14 | Filing | |
| $1.28 | 400,000 | Director | 1,731,874 | 2023-05-18 | Filing | |
| $1.28 | 350,000 | Director | 420,921 | 2023-05-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.72 | 324 | Officer | 7,288 | 2025-01-06 | Filing | |
| $11.72 | 645 | Officer | 33,216 | 2025-01-06 | Filing | |
| $9.64 | 330 | Officer | 6,869 | 2024-12-04 | Filing | |
| $9.64 | 741 | Officer | 32,386 | 2024-12-04 | Filing | |
| $7.58 | 333 | Officer | 6,456 | 2024-11-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% |
News See All
10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds
The pharmaceutical industry remains a hub of patent innovation, driven by evolving treatment paradigms, unmet medical needs, and the rising influence of technologies like pharmacogenomics, digital therapeutics...
10 High Risk High Reward Growth Stocks Stocks To Buy
When it comes to making money on the stock market, most investors are typically attracted to growth stocks.
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q2 2024 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q2 2024 Earnings Call Transcript August 8, 2024Ginkgo Bioworks Holdings, Inc. misses on earnings expectations.
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q1 2024 Earnings Call Transcript
Megan LeDuc: Good evening, I’m Megan LeDuc, Manager of Investor Relations at Ginkgo Bioworks. I’m joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO.
16 Best US Stocks To Invest In Under $10
In March 2024, the S&P 500 surged with a total return of 3.2%, marking the first quarter's closure with a record high not seen since 2019.
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q4 2023 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. reports earnings inline with expectations. Reported EPS is $-0.09 EPS, expectations were $-0.09. Ginkgo Bioworks Holdings, Inc.
12 Best NYSE Penny Stocks To Buy
Markets wavered as latest data showed inflation in January 2024 was hotter-than-expected.
5 Hot Healthcare Stocks To Buy Now
In this article, we will be taking a look at 5 hot healthcare stocks to buy now.
Ark Invest Stock Portfolio: 16 Biggest Positions
In this article, we discuss the 16 biggest positions in the ARK Invest portfolio.
Billionaire Hedge Funds
